Midazolam Injection / Rafa - LARVOL DELTA

Impact of midazolam on salivary glands: a comprehensive analysis of oxidative biochemistry, morphological changes, and salivary composition. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "In both glands, MDZ caused a reduction in the parenchymal area, an increase in the stromal area, and a reduction of in acinar area and size. In saliva, MDZ reduced trolox equivalent antioxidant capacity levels, and decreased the activity of salivary amylase. As a result of this study, we conclude that MDZ can trigger biochemical and morphological changes in the parotid and submandibular glands, as well as functional impairment and modulation of oxidative biochemistry in total saliva. With this, our pre-clinical study points to changes that could have an impact on biological processes such as tooth decay and food digestion."

Journal • Dental Disorders

Prevalence of potentially inappropriate medications and prescription dynamics in elderly hospitalized patients in Spain. (PubMed, BMC Geriatr) - "In this population of older hospitalized patients, the overall prevalence of PIMs was moderate. However, the prevalence rate at the participating hospitals was highly variable. In most cases, PIMs prescribed prior to hospitalization for chronic conditions were not withdrawn during the hospital stay. No significant increase in PIMs was observed from pre-admission to post-discharge. These findings underscore the need for multidisciplinary interventions to optimize the pharmaceutical treatment in older adults in the hospital setting to reduce the consequences of PIMs in patients."

Journal

Rafa Receives FDA Approval For Life-saving Midazolam Autoinjector (PRNewswire) - "Rafa Laboratories LTD...is pleased to announce the U.S. Food and Drug Administration has approved its 'first in market' 10 mg midazolam autoinjector for the treatment of status epilepticus in adults."

NDA • CNS Disorders • Epilepsy